These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

140 related items for PubMed ID: 3391218

  • 1. Cyclophosphamide in treatment of minimal change nephrotic syndrome.
    Shohet I, Meyerovitch J, Aladjem M, Boichis H.
    Eur J Pediatr; 1988 Apr; 147(3):239-41. PubMed ID: 3391218
    [Abstract] [Full Text] [Related]

  • 2. Pattern of response to prednisone in idiopathic, minimal lesion nephrotic syndrome as a criterion in selecting patients for cyclophosphamide therapy.
    Garin EH, Pryor ND, Fennell RS, Richard GA.
    J Pediatr; 1978 Feb; 92(2):304-8. PubMed ID: 621614
    [Abstract] [Full Text] [Related]

  • 3. Conventional therapy for idiopathic nephrotic syndrome in children.
    Brodehl J.
    Clin Nephrol; 1991 Feb; 35 Suppl 1():S8-15. PubMed ID: 1860269
    [Abstract] [Full Text] [Related]

  • 4. Predicting the response to cytotoxic therapy for childhood nephrotic syndrome: superiority of response to corticosteroid therapy over histopathologic patterns.
    Schulman SL, Kaiser BA, Polinsky MS, Srinivasan R, Baluarte HJ.
    J Pediatr; 1988 Dec; 113(6):996-1001. PubMed ID: 3193322
    [Abstract] [Full Text] [Related]

  • 5. The long-term outlook to final outcome and steroid treatment results in children with idiopathic nephrotic syndrome.
    Dinçel N, Yılmaz E, Kaplan Bulut İ, Hacıkara Ş, Mir S.
    Ren Fail; 2015 Dec; 37(8):1267-72. PubMed ID: 26313331
    [Abstract] [Full Text] [Related]

  • 6. Beneficial effect of chlorambucil in steroid-dependent and cyclophosphamide-resistant minimal change nephrotic syndrome.
    Ueda N, Takahashi K, Akioka Y, Morooka M, Ogawa A, Tsuzuki K.
    J Nephrol; 2009 Dec; 22(5):610-5. PubMed ID: 19809993
    [Abstract] [Full Text] [Related]

  • 7. Pulse cyclophosphamide inadequately suppresses reoccurrence of minimal change nephrotic syndrome in corticoid-dependent children.
    Donia AF, Gazareen SH, Ahmed HA, Moustafa FE, Shoeib AA, Ismail AM, Khamis S, Sobh MA.
    Nephrol Dial Transplant; 2003 Oct; 18(10):2054-8. PubMed ID: 13679480
    [Abstract] [Full Text] [Related]

  • 8. Beneficial effect of second courses of cytotoxic therapy in children with minimal change nephrotic syndrome.
    Jones DP, Stapleton FB, Roy S, Wyatt RJ.
    Pediatr Nephrol; 1988 Jul; 2(3):291-5. PubMed ID: 3153028
    [Abstract] [Full Text] [Related]

  • 9. Intravenous pulse cyclophosphamide--a new regime for steroid-resistant minimal change nephrotic syndrome.
    Elhence R, Gulati S, Kher V, Gupta A, Sharma RK.
    Pediatr Nephrol; 1994 Feb; 8(1):1-3. PubMed ID: 8142205
    [Abstract] [Full Text] [Related]

  • 10. The treatment of minimal change nephrotic syndrome (lipoid nephrosis): cooperative studies of the Arbeitsgemeinschaft für Pädiatrische Nephrologie (APN).
    Brodehl J, Krohn HP, Ehrich JH.
    Klin Padiatr; 1982 Feb; 194(3):162-5. PubMed ID: 6752557
    [Abstract] [Full Text] [Related]

  • 11. Tacrolimus versus intravenous pulse cyclophosphamide therapy in Chinese adults with steroid-resistant idiopathic minimal change nephropathy: a multicenter, open-label, nonrandomized cohort trial.
    Li H, Shi X, Shen H, Li X, Wang H, Li H, Xu G, Chen J.
    Clin Ther; 2012 May; 34(5):1112-20. PubMed ID: 22503105
    [Abstract] [Full Text] [Related]

  • 12. Daily single-dose and daily reduced-dose prednisone therapy for children with the nephrotic syndrome.
    Warshaw BL, Hymes LC.
    Pediatrics; 1989 May; 83(5):694-9. PubMed ID: 2717285
    [Abstract] [Full Text] [Related]

  • 13. [Good results of cyclophosphamide in steroid toxicity in the treatment of nephrotic syndrome caused by minimal-lesion glomerulopathy in childhood].
    de Moor R, de Jong M, Monnens L.
    Ned Tijdschr Geneeskd; 1992 May 02; 136(18):876-80. PubMed ID: 1589052
    [Abstract] [Full Text] [Related]

  • 14. Long-term follow-up of cyclophosphamide therapy in frequent relapsing minimal lesion nephrotic syndrome.
    Chiu J, Drummond KN.
    J Pediatr; 1974 Jun 02; 84(6):825-30. PubMed ID: 4855503
    [No Abstract] [Full Text] [Related]

  • 15. Long-term assessment of cyclophosphamide therapy for nephrosis in children.
    McDonald J, Murphy AV, Arneil GC.
    Lancet; 1974 Oct 26; 2(7887):980-2. PubMed ID: 4138088
    [No Abstract] [Full Text] [Related]

  • 16. Single-center experience with cyclosporine for treatment of idiopathic minimal change nephrotic syndrome in children.
    Sabry A, El-Husseini A, El-Dahshan K, Sobh M.
    Iran J Kidney Dis; 2009 Jul 26; 3(3):127-35. PubMed ID: 19617660
    [Abstract] [Full Text] [Related]

  • 17. Tacrolimus as a steroid-sparing agent for adults with steroid-dependent minimal change nephrotic syndrome.
    Li X, Li H, Chen J, He Q, Lv R, Lin W, Li Q, He X, Qu L, Suya W.
    Nephrol Dial Transplant; 2008 Jun 26; 23(6):1919-25. PubMed ID: 17911091
    [Abstract] [Full Text] [Related]

  • 18. The treatment of minimal change nephrotic syndrome: lessons learned from multicentre co-operative studies.
    Brodehl J.
    Eur J Pediatr; 1991 Apr 26; 150(6):380-7. PubMed ID: 2040345
    [Abstract] [Full Text] [Related]

  • 19. Eight and 12 week courses of cyclophosphamide in nephrotic syndrome.
    Ueda N, Kuno K, Ito S.
    Arch Dis Child; 1990 Oct 26; 65(10):1147-50. PubMed ID: 2248508
    [Abstract] [Full Text] [Related]

  • 20. Late resistance to corticosteroids in nephrotic syndrome.
    Srivastava RN, Agarwal RK, Moudgil A, Bhuyan UN.
    J Pediatr; 1986 Jan 26; 108(1):66-70. PubMed ID: 3944696
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.